We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

YM BioSciences Reports Positive Interim Data from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387

News   Dec 07, 2010

 
YM BioSciences Reports Positive Interim Data from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
 
 
 

RELATED ARTICLES

Drug Cocktail Could Increase Lifespan

News

A team of researchers has discovered a combination of pharmaceutical drugs that not only increases healthy lifespan in the microscopic worm Caenorhabditis elegans (C. elegans), but also delays the rate of ageing in them, a finding that could someday mean longer, healthier lives for humans.

READ MORE

Aspirin Stops Clots After Knee Surgery

News

Putting patients on aspirin following a knee replacement is a safe, cost-effective alternative to anticoagulants, U-M researchers find.

READ MORE

Treating the Prostate with Radiotherapy Improves Survival

News

Treating the prostate with radiotherapy alongside standard treatment led to a 11 percent increase in survival for some men with advanced prostate cancer, shows trial.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE